915201-19-3

Upstream product

• 915201-18-2 (2R,4R,6R)-4-tert-butyldiphenylsilyloxy-2-cyanomethyl-6-methoxytetrahydropyran 
• 91312-53-7 ethyl (3R,5S)-5,6-O-isopropylidene-3,5,6-trihydroxyhexanoate 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 86030-94-6 methyl 3-O-(tert-butyldiphenylsilyl)-2,4-dideoxy-β-D-erythro-hexopyranoside 
• 915201-15-9 ethyl (3R,5S)-3-tert-butyldiphenylsilyloxy-5,6-(isopropylidenedioxy)hexanoate 
• 915201-17-1 (2S,4R,6S)-2-(p-chlorobenzenesulfonyloxy)methyl-4-tert-butyldiphenylsilyloxy-6-methoxytetrahydropyran 
• 915201-16-0 (3R,5S)-3-tert-butyldiphenylsilyloxy-5,6-(isopropylidenedioxy)hexanal 

Relevant academic research and scientific papers

Highly stereoselective hydrogenations-as key-steps in the total synthesis of statins

Statins are inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMG-CoA reductase) and became the standard of care for treatment of hypercholesterolemia because of their efficacy, safety, and long-term benefits. They are administered as diaste

METHOD FOR THE PRODUCTION OF STATINS

The invention relates to a method for producing statins known as HMG-CoA reductase inhibitors. Some of the intermediate compounds used in the inventive method are novel compounds. The invention also relates to said novel intermediate compounds.

Synthesis of the chiral side chain of statins - Lactone versus lactol pathway

4-O-Protected (4R,6S)-4-hydroxy-6-(hydroxymethyl)tetrahydropyran-2-ones (3) derived from enantiomerically pure (3R,5S)-3-hydroxy-5,6-(isopropylidenedioxy) hexanoates (2) are frequently considered as pivotal intermediates for the synthesis of pharmacologic